Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Clinical Trials

Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma

Phase 3

Conditions: Non-Hodgkin Lymphoma by Clinical Course

Interventions: Drug: Bendamustine

First Posted Date: 2012-04-04

Last Posted Date: 2012-08-02

Lead Sponsor: Shandong Lanjin Pharmaceuticals Co.,Ltd

Target Recruit Count: 100

Registration Number: NCT01570049

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Idelalisib
Drug: Rituximab
Drug: Bendamustine
Drug: Placebo to match idelalisib

First Posted Date: 2012-04-03

Last Posted Date: 2020-03-10

Lead Sponsor: Gilead Sciences

Target Recruit Count: 416

Registration Number: NCT01569295

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇬🇧
University College London, London, United Kingdom
🇬🇷
G. Genimatas Hospital, Athens, Greece

and more 101 locations

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma
Adult Lymphocyte Predominant Hodgkin Lymphoma
Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma
Adult Nodular Sclerosis Hodgkin Lymphoma
Recurrent Adult Hodgkin Lymphoma
Adult Mixed Cellularity Hodgkin Lymphoma

Interventions: Drug: gemcitabine hydrochloride
Drug: bendamustine hydrochloride

First Posted Date: 2012-02-20

Last Posted Date: 2021-11-19

Lead Sponsor: Beth Christian

Target Recruit Count: 26

Registration Number: NCT01535924

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bendamustine
Drug: Thalidomide
Drug: Dexamethasone

First Posted Date: 2012-02-06

Last Posted Date: 2018-07-03

Lead Sponsor: Azienda Ospedaliera di Bolzano

Target Recruit Count: 30

Registration Number: NCT01526694

Locations: 🇮🇹
AULSS 2 Feltre, Feltre, Italy
🇮🇹
Ospedale Ca Foncello, Treviso, Italy
🇮🇹
Ospedale dell'Angelo di Mestre, Mestre, Italy

and more 16 locations

Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma

Phase 2

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: Rituximab, Mitoxantrone, Bendamustine

First Posted Date: 2012-02-01

Last Posted Date: 2016-03-01

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 76

Registration Number: NCT01523860

Locations: 🇮🇹
Oncologia Medica ed Ematologia, Istituto Clinica Humanitas, Rozzano, Milano, Italy
🇮🇹
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Forlì-Cesena, Italy
🇮🇹
UO Oncologia ed Onco-Ematologia, Ospedale di Rimini, Rimini, Rn, Italy

and more 34 locations